Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics (LXEO) filed a resale registration covering up to 1,250,015 shares of common stock. The shares are issuable upon exercise of outstanding pre-funded warrants held by a single selling stockholder and may be sold from time to time by that holder.
Lexeo is not selling any shares in this filing and will not receive proceeds from the selling stockholder’s sales. The company would receive nominal cash equal to the $0.0001 per-share exercise price only if the pre-funded warrants are exercised for cash; the warrants may also be exercised on a cashless basis under certain conditions.
The pre-funded warrants were issued in an October 2025 private placement at $7.9999 per warrant for aggregate proceeds of approximately $10 million. They are exercisable at any time, subject to a 9.99% beneficial ownership limit that the holder may reset up to 19.99% effective 61 days after notice. LXEO’s common stock trades on Nasdaq under “LXEO,” with a last quoted sale price of $8.35 on November 4, 2025.
Lexeo Therapeutics (LXEO) filed a Form S-8 to register 2,000,000 shares of common stock reserved for issuance under the 2025 Inducement Equity Incentive Plan. The plan is intended for equity awards granted as hiring inducements outside stockholder-approved plans.
This is an administrative registration to facilitate future employee equity awards, not a public offering. The filing includes customary legal opinions and consents.
Lexeo Therapeutics (LXEO) reported Q3 2025 results with a net loss of $20.3 million (basic and diluted $0.33 per share). Operating expenses were $21.6 million, driven by $15.7 million in research and development and $6.0 million in general and administrative costs. Other income reflected $1.5 million of interest income.
As of September 30, 2025, cash, cash equivalents and investments in U.S. Treasury securities totaled $122.8 million (cash and cash equivalents $41.0 million; current Treasuries $81.8 million). Management estimates these resources are sufficient to fund operations for at least 12 months from the issuance date. The company received net proceeds of $73.1 million from a May 2025 private placement during the period, and subsequently added $143.9 million of estimated net proceeds in October 2025 financing transactions. An at-the-market program for up to $75.0 million was in place with no sales through quarter end. Shares outstanding were 72,987,327 as of November 3, 2025.
Lexeo Therapeutics (LXEO) furnished an 8-K announcing it issued a press release with business highlights and financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference. The company states the information under Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed filed under the Exchange Act. LXEO’s common stock trades on the Nasdaq Global Market.
Lexeo Therapeutics (LXEO) insider filing: the Chief Development Officer reported equity transactions on a Form 4. On 10/15/2025, the officer acquired 10,890 shares of Common Stock at $0, reflecting the release of RSUs. On 10/17/2025, the officer sold 3,844 shares at a weighted average price of $8.935 (executed between $8.53 and $9.52) and 44 shares at a weighted average price of $9.561 (executed between $9.53 and $9.59). The filing states the sales were to cover tax obligations upon RSU release. Following these transactions, the officer beneficially owned 65,862 shares directly, which includes 49,138 RSUs, each representing a right to receive one share.
Lexeo Therapeutics (LXEO) insider activity: the Chief Legal Officer reported acquiring 9,900 shares of common stock on 10/15/2025 at $0, and selling shares to cover tax obligations on released RSUs.
On 10/17/2025, the officer sold 3,486 shares at a weighted average price of $8.935 (trades ranged from $8.53 to $9.52) and 40 shares at a weighted average price of $9.561 (trades ranged from $9.53 to $9.59). Following these transactions, beneficial ownership was 68,930 shares, which includes 51,092 RSUs, with each RSU representing a right to one share.
Lexeo Therapeutics (LXEO): insider transaction disclosed. The company’s Chief Technical Officer filed a Form 4 showing 5,940 shares of common stock acquired on 10/15/2025 at a price of $0. Following this, sales on 10/17/2025 totaled 2,091 shares at a weighted average price of $8.935 and 24 shares at a weighted average price of $9.561, with both ranges detailed in the notes. The filing states the sales represent shares sold to cover tax obligations on the release of RSUs.
After these transactions, the reporting person beneficially owned 64,197 shares directly, which includes 49,687 RSUs, each representing a contingent right to one share of common stock.
Lexeo Therapeutics (LXEO) reported insider activity by its Chief Medical Officer on a Form 4. On 10/15/2025, 9,570 shares of Common Stock were acquired at $0 upon the release of Restricted Stock Units. On 10/17/2025, the officer sold 3,344 shares at a weighted average price of $8.935 and 38 shares at a weighted average price of $9.561; the filing states these sales were to cover tax obligations related to the RSU release.
After the transactions, beneficial ownership was 73,261 shares, which includes 60,546 RSUs.
Lexeo Therapeutics (LXEO) reported insider activity by its Chief Executive Officer and Director. On 10/15/2025, the reporting person acquired 33,000 shares of Common Stock at $0 upon RSU release. On 10/17/2025, shares were sold to cover taxes in open market transactions: 12,985 shares at a weighted average price of $8.935 and 148 shares at a weighted average price of $9.561. Following these transactions, beneficial ownership stands at 242,118 shares, which includes 131,092 RSUs, held directly.
Lexeo Therapeutics priced a public offering of 15,625,000 common shares at $8.00 per share, with underwriters purchasing at $7.52. The company granted a 30‑day option for up to 2,343,750 additional shares. Gross proceeds are expected to be approximately $125 million before fees, with closing targeted for October 20, 2025.
Separately, Lexeo agreed to sell 1,250,015 pre‑funded warrants in a private placement for approximately $10 million; the warrants are immediately exercisable at $0.0001 per share and include a 9.99% beneficial ownership cap, adjustable up to 19.99%. As of September 30, 2025, the company estimated $122.8 million in cash, cash equivalents and investments.
Clinical updates: for LX2006, the FDA indicated openness to an accelerated approval BLA using pooled Phase I/II and pivotal data, contingent on enhanced comparability and nonclinical requirements. For LX2020, nine participants have been dosed; the program has been generally well tolerated with one Grade 3 serious adverse event possibly treatment related. Additional safety and efficacy data are expected in January 2026.